Pergamum initiates Phase II trial with DPK-060 in outer ear infections
(Thomson Reuters ONE) -
STOCKHOLM, SWEDEN - January 16, 2012. Pergamum AB today announced that the first
patient has been dosed in a randomized Phase II study of DPK-060 for the
treatment of patients with external otitis (swimmers ear).
"Every year more than 10 million people world-wide seek medical care for
treatment of infections in the outer ear. There is a significant medical need to
avoid rapidly increasing global prevalence of antibiotics resistance that limits
the therapeutic value of conventional products, and we think that we can meet
this need with DPK-060", says Jonas Ekblom, CEO of Pergamum
Pergamum's Phase II-study is a double-blind, randomized, placebo-controlled,
multi-center trial in patients with acute external otitis. The objectives of the
trial are to assess the efficacy, local tolerability and safety of DPK-060 ear
drops in infections caused by bacterial or fungal pathogens. The trial is
expected to enroll approximately 70 patients. The principal investigator for
this trial is Dr. Pekka Koskinen, who is Managing Director at the Center för
Läkemedelsstudier, Malmö, Sweden.
DPK-060 is a novel anti-microbial peptide which is structurally derived from the
endogenous human protein kininogen. It has a broad-spectrum action on bacteria
such as Staphylococcus aureus, including multidrug-resistant strains, as well as
fungi such as Candida and Malassezia. DPK-060 has shown positive data in a
clinical Phase II study in atopic dermatitis and has the potential to treat many
other dermatological conditions where these microorganisms are a major problem.
"Pergamum has developed a new class of broad-spectrum-acting antimicrobial
agents based on a peptide from the body's own defence system", says Torbjörn
Bjerke, Chairman of the board in Pergamum and CEO of Karolinska Development AB.
"The results of this clinical study is an important step towards a potential new
prescription product for topical application that could change the treatment of
skin infections, not only in the field of external otitis, but also in several
other infections under investigation by Pergamum."
For further information, please contact:
Jonas Ekblom, President and CEO, Pergamum AB
Phone: +46 (0)70 551 66 60, e-mail: jonas.ekblom(at)pergamum.com
Torbjörn Bjerke, CEO, Karolinska Development AB
Phone: +46 (0)72 744 41 23, e-mail: torbjorn.bjerke(at)karolinskadevelopment.com
TO THE EDITORS
About Pergamum AB
Pergamum is a biopharmaceutical company specialized in the development of
therapeutic peptides for treatment of skin infections and wounds. Within
Pergamum, companies and projects are managed as fully integrated operating units
with access to a core team of experienced professionals within drug development
and business management. This model provides Pergamum with an attractive
diversified product pipeline while minimizing development cost and time-to-
market and mitigating risk. Three programs are currently in clinical phase.
www.pergamum.com
About Karolinska Development AB
Karolinska Development aims to create value for investors, patients, and
researchers by developing innovations from world class science into products
that can be sold or out-licensed with high returns. The business model is to:
SELECT the most commercially attractive medical innovations; DEVELOP innovations
to the stage where the greatest return on investment can be achieved; and
COMMERCIALIZE the innovations through the sale of companies or out-licensing of
products. An exclusive deal flow agreement with Karolinska Institutet
Innovations AB, along with other cooperation agreements with leading Nordic
universities, delivers a continuous flow of innovations. Today, the portfolio
consists of 34 projects, of which 14 are in clinical development. For more
information, please visit www.karolinskadevelopment.com.
Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be
required to disclose the information provided herein pursuant to the Securities
Markets Act.
Press release as PDF:
http://hugin.info/143071/R/1577674/492036.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Karolinska Development AB (publ) via Thomson Reuters ONE
[HUG#1577674]
Unternehmensinformation / Kurzprofil:
Datum: 16.01.2012 - 07:01 Uhr
Sprache: Deutsch
News-ID 104160
Anzahl Zeichen: 5072
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 289 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pergamum initiates Phase II trial with DPK-060 in outer ear infections"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
